Study 67
 

Antitumour potential of pollen extract on Lewis lung carcinoma implanted intraperitoneally in syngeneic mice

Furusawa-E; Chou-SC; Hirazumi-A; Melera-A

Department of Pharmacology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA.

Phytotherapy-Research. 1995, 9:4, 255-259; 26 ref.

A defined pollen extract of selected plants is used to treat chronic prostatis or benign hyperplasia. The antineoplastic potential of the water-soluble fraction ( T60) of the pollen extract against Lewis lung carcinoma implanted i.p. in syngeneic mice was investigated. T60 was not cytotoxic against KB cells at concentrations up to 2.5 mg/ml. T60 (0.5 g/kg) significantly prolonged the lifespan of mice carrying the tumour without any apparent side effects. T60 demonstrated beneficial therapeutic effects in an additive fashion on the life-span of mice when it was combined with standard cytotoxic antineoplastic drugs such as adriamycin [doxorubicin], cisplatin, vincristine, methotrexate, fluorouracil, or thioguanine. The antineoplastic potential of T60 was completely abolished by treatment with inhibitors of macrophage functions (2-chloroadenosine or carrageenan); the antineoplastic potential of T60 was not abolished following treatment with the T-cell inhibitor, cyclosporin A. T60 appears to be a potent immunostimulator of macrophages.